CN109952290A - Fgfr4 抑制剂及其制备方法和应用 - Google Patents

Fgfr4 抑制剂及其制备方法和应用 Download PDF

Info

Publication number
CN109952290A
CN109952290A CN201780070537.7A CN201780070537A CN109952290A CN 109952290 A CN109952290 A CN 109952290A CN 201780070537 A CN201780070537 A CN 201780070537A CN 109952290 A CN109952290 A CN 109952290A
Authority
CN
China
Prior art keywords
milliliters
milligrams
compound
mms
grams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780070537.7A
Other languages
English (en)
Other versions
CN109952290B (zh
Inventor
陈正霞
龙超峰
张杨
陈小新
王一恺
戴美碧
刘卓伟
赵海霞
刘星
胡国平
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN109952290A publication Critical patent/CN109952290A/zh
Application granted granted Critical
Publication of CN109952290B publication Critical patent/CN109952290B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

提供一类作为FGFR4抑制剂的式(I)所示化合物及其药学上可接受的盐，其制备方法及其在制备治疗FGFR4相关病症的药物上的应用。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201780070537.7A 2016-11-17 2017-11-17 Fgfr4抑制剂及其制备方法和应用 Active CN109952290B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611012431 2016-11-17
CN2016110124315 2016-11-17
PCT/CN2017/111634 WO2018090973A1 (zh) 2016-11-17 2017-11-17 Fgfr4抑制剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN109952290A true CN109952290A (zh) 2019-06-28
CN109952290B CN109952290B (zh) 2022-05-03

Family

ID=62145242

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780070537.7A Active CN109952290B (zh) 2016-11-17 2017-11-17 Fgfr4抑制剂及其制备方法和应用

Country Status (12)

Country Link
US (1) US11008292B2 (zh)
EP (1) EP3543227B1 (zh)
JP (1) JP7063899B2 (zh)
KR (1) KR102249632B1 (zh)
CN (1) CN109952290B (zh)
AU (1) AU2017359819B2 (zh)
CA (1) CA3043948C (zh)
IL (1) IL266659B (zh)
MX (1) MX2019005723A (zh)
NZ (1) NZ754218A (zh)
WO (1) WO2018090973A1 (zh)
ZA (1) ZA201903845B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101503233B1 (ko) 2013-09-30 2015-03-18 주식회사화신 부시 압입장치
US11440903B2 (en) 2017-11-01 2022-09-13 Guangdong Zhongsheng Pharmaceutical Co., Ltd Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007082434A1 (fr) * 2006-01-20 2007-07-26 Shanghai Allist Pharmaceutical., Inc. Dérivés de quinazoline, leurs procédés de fabrication et utilisations
WO2012136099A1 (zh) * 2011-04-02 2012-10-11 齐鲁制药有限公司 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
WO2014139465A1 (en) * 2013-03-15 2014-09-18 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and their usage
WO2016115412A1 (en) * 2015-01-18 2016-07-21 Newave Pharmaceutical Llc Dual-warhead covalent inhibitors of fgfr-4
CN105899490A (zh) * 2013-10-18 2016-08-24 卫材R&D管理有限公司 嘧啶fgfr4抑制剂
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014011900A2 (en) 2012-07-11 2014-01-16 Blueprint Medicines Inhibitors of the fibroblast growth factor receptor
SG11201708472WA (en) 2015-04-14 2017-11-29 Eisai R&D Man Co Ltd Crystalline fgfr4 inhibitor compound and uses thereof
US11440903B2 (en) * 2017-11-01 2022-09-13 Guangdong Zhongsheng Pharmaceutical Co., Ltd Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007082434A1 (fr) * 2006-01-20 2007-07-26 Shanghai Allist Pharmaceutical., Inc. Dérivés de quinazoline, leurs procédés de fabrication et utilisations
WO2012136099A1 (zh) * 2011-04-02 2012-10-11 齐鲁制药有限公司 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
WO2014139465A1 (en) * 2013-03-15 2014-09-18 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and their usage
CN105899490A (zh) * 2013-10-18 2016-08-24 卫材R&D管理有限公司 嘧啶fgfr4抑制剂
WO2016115412A1 (en) * 2015-01-18 2016-07-21 Newave Pharmaceutical Llc Dual-warhead covalent inhibitors of fgfr-4
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors

Also Published As

Publication number Publication date
CA3043948C (en) 2021-08-31
MX2019005723A (es) 2019-10-21
JP7063899B2 (ja) 2022-05-09
CN109952290B (zh) 2022-05-03
EP3543227A4 (en) 2019-10-30
AU2017359819A1 (en) 2019-06-20
KR102249632B1 (ko) 2021-05-10
IL266659B (en) 2022-01-01
IL266659A (en) 2019-07-31
WO2018090973A1 (zh) 2018-05-24
NZ754218A (en) 2021-07-30
ZA201903845B (en) 2020-12-23
KR20190077085A (ko) 2019-07-02
US20200062716A1 (en) 2020-02-27
AU2017359819B2 (en) 2020-05-28
EP3543227B1 (en) 2020-12-30
US11008292B2 (en) 2021-05-18
CA3043948A1 (en) 2018-05-24
JP2019537613A (ja) 2019-12-26
EP3543227A1 (en) 2019-09-25

Similar Documents

Publication Publication Date Title
JP6726677B2 (ja) 抗がん剤としての置換２−ｈ−ピラゾール誘導体
CN107531695B (zh) Jak抑制剂
AU2017239481A1 (en) DNA-PK inhibitors
CN109071538A (zh) 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
EP3333157B1 (en) Vinyl compounds as fgfr and vegfr inhibitors
CN109983016B (zh) 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
KR20150128842A (ko) 브로모도메인 억제제로서의 퓨로피리딘
CN107614503A (zh) 稠环或三环芳基嘧啶化合物用作激酶抑制剂
US20220259235A1 (en) EGFR Inhibitor, Composition, and Preparation Method Therefor
CN109890820A (zh) 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物
KR20130122778A (ko) FAK/Pyk2 억제제인 2,4-디아미노-6,7-디히드로-5H-피롤로[2,3]피리미딘 유도체
CN104926788B (zh) 取代哌啶类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CN109415341A (zh) 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
CN107108586B (zh) 多环类间变性淋巴瘤激酶抑制剂
KR20170054421A (ko) 브로모도메인 억제제로서의 테트라하이드로퀴놀린 유도체
CN112313207B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
CN109952290A (zh) Fgfr4 抑制剂及其制备方法和应用
JP2024502178A (ja) Ｓｇｋ－１を阻害するためのピラゾロ［３，４－ｄ］ピリミジン－６－イル－スルホンアミド誘導体
CN108864081A (zh) Fgfr4抑制剂及其制备与应用
CN110418790A (zh) 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物
CN103965211A (zh) 含喹唑啉结构的三环类衍生物及其制备方法和用途
CN115785154A (zh) 杂芳环化合物及其医药用途
JP7477846B2 (ja) Ｎを含むヘテロアリール誘導体およびこれを有効成分として含むがんの予防または治療用薬学的組成物
TW202310845A (zh) 雜芳基衍生化合物及其用途
CN104995183B (zh) 新的磷酸二酯酶10a型的抑制剂化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004140

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant